Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032753 · ClinicalTrials.gov registry record · NA
Neuromusculoskeletal Interface for Bionic Arms
A NA study, sponsored by Shirley Ryan AbilityLab.
- Not yet
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT07032753: Clinical Trial NA study, sponsored by Shirley Ryan AbilityLab.
NCT07032753 is a NA study that has not yet begun recruiting, run by Shirley Ryan AbilityLab. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07032753, a NA study, has not yet begun recruiting, sponsored by Shirley Ryan AbilityLab.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall objective of this proposal is to perform a first-in-human home trial of the Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations who have had Targeted Muscle Reinnervation (TMR) surgery and use a pattern recognition-controlled myoelectric prosthesis. The purpose of the study is to capture preliminary safety and effectiveness information on the e-OPRA device when used with the prosthetic systems. The investigators expect that the e-OPRA implant system will be safe and provide clinically and statistically significant improvements in control and comfort. Specifically, the investigators hypothesize that the e-OPRA system will (1) allow for training of more functional prosthesis controllers, (2) provide more stable electromyographic (EMG) signals, reducing the need to recalibrate the prosthetic control system, and (3) be more comfortable, as it does not require a tethered arm-band to record surface EMG signals. Phase 1: Perform TMR and e-OPRA surgeries in 8 persons with transhumeral amputations. Phase 2: Perform a randomized cross-over study to compare the OPRA and e-OPRA system (without sensory feedback) in 8 transhumeral amputees who have received TMR. Phase 3: Perform a randomized cross-over study to compare the e-OPRA system with and without sensory feedback in 8 transhumeral amputees who have received TMR.
Primary Outcome
The number/percentage of subjects that successfully demonstrate the absence of any Serious Adverse Device Effects will be summarized along with a 95% confidence interval.
Interventions
- DEVICE OPRA
- DEVICE eOPRA
- DEVICE eOPRA with sensory feedback
- DEVICE eOPRA without sensory feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2029-05-31 |
| Phase | NA |
What is known before NCT07032753 opens enrollment
NCT07032753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which OPRA is the first listed.
NCT07032753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07032753 about?
NCT07032753 is a clinical study titled "Neuromusculoskeletal Interface for Bionic Arms". The overall objective of this proposal is to perform a first-in-human home trial of the Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations who have had Targeted Muscle Reinnervation (TMR) surgery and use a patte...
What is the current status of trial NCT07032753?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2026-01-01. Estimated completion is 2029-05-31.
What interventions are being tested in trial NCT07032753?
The interventions under investigation include: OPRA (DEVICE), eOPRA (DEVICE), eOPRA with sensory feedback (DEVICE), eOPRA without sensory feedback (DEVICE).
Who is sponsoring clinical trial NCT07032753?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07032753's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI